|
AU2003253632A1
|
|
Genes overexpressed by ovarian cancer and their use in developing novel therapeutics
|
|
AU2003222103A1
|
|
Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas
|
|
ZA200302139B
|
|
Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory anti-body combination.
|
|
AU2003217421A8
|
|
Prostate specific genes and the use thereof in design or therapeutics
|
|
ZA200300293B
|
|
Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications.
|
|
AU2002359777A1
|
|
Genes overexpresses by ovarian cancer and their use in developing novel therapeutics especially antibodies
|
|
US2003157641A1
|
|
Polycistronic expression of antibodies
|
|
AU2002346373A1
|
|
Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
|
|
US2003180290A1
|
|
Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
|
|
EA007467B1
|
|
Use of cd23 antagonists for the treatment of neoplastic disorders
|
|
AU2002327164A1
|
|
Engineered tetravalent antibodies and methods of use
|
|
PL372140A1
|
|
Modified antibodies and methods of use
|
|
US2002193569A1
|
|
Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
|
|
AU1335702A
|
|
Variant igg3 rituxan r and therapeutic use thereof
|
|
IL154845D0
|
|
Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory combination
|
|
WO0222212A2
|
|
Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
|
|
WO0197858A2
|
|
Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
|
AU7543701A
|
|
Novel gene targets and ligands that bind thereto for treatment and diagnosis of ovarian carcinomas
|
|
WO0194586A2
|
|
Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
|
|
WO0197844A1
|
|
Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
|
